Ever hear of FUSN? They just got taken out for $2.4B The key here is their conjugate targeting technology or the 'heat seeking missle' to deliver a payload. Pfizer already did that with Seagen and LABS will be providing pharmaceutical grade cannabinoids. The same structural framework methodology using conjugates for targeted payload delivery and what you put inside the peptide, a radioactive component or cannabinoid acid is merely the contents.
Just to give you a taste of how fast things potentially can happen to LABS and their global pharma partner.
Fusion shareholders to receive $21.00 per share in cash at closing plus a non-transferrable contingent value right (CVR) of $3.00 per share, representing a total transaction value of approximately $2.4 billion including the CVR
HAMILTON, ON and BOSTON, March 19, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive agreement to be acquired by AstraZeneca. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
RCs have emerged as a promising modality in cancer treatment over recent years. These medicines deliver a radioactive isotope directly to cancer cells through precise targeting using molecules such as antibodies, peptides or small molecules. This approach has many potential advantages compared to traditional radiotherapy, including minimizing damage to healthy cells and enabling access to tumors not reachable through external beam radiation.